| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/08/2009 | CA2692320A1 Methods of treating bone disorders with modulators of axl |
| 01/08/2009 | CA2692287A1 Treatment of rheumatoid arthritis |
| 01/08/2009 | CA2692268A1 Substituted piperazines as cb1 antagonists |
| 01/08/2009 | CA2692265A1 Amide compounds |
| 01/08/2009 | CA2692260A1 Macrolactone derivatives |
| 01/08/2009 | CA2692253A1 Gamma secretase modulators |
| 01/08/2009 | CA2692160A1 Salts of potassium atp channel openers and uses thereof |
| 01/08/2009 | CA2692153A1 Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
| 01/08/2009 | CA2692146A1 Dual portion lozenge dosage form |
| 01/08/2009 | CA2692145A1 Antiviral compounds |
| 01/08/2009 | CA2692101A1 Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and a compound that inhibits a ugt pathway or ugt metabolism |
| 01/08/2009 | CA2691973A1 A method for decreasing symptoms of alcohol consumption |
| 01/08/2009 | CA2691954A1 Novel 4-{3-[4-(3-{4-[amino(butoxycarbonylimino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}-n'-(butoxycarbonyl) benzamidine crystals |
| 01/08/2009 | CA2691943A1 Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
| 01/08/2009 | CA2691844A1 Therapeutic compound |
| 01/08/2009 | CA2691812A1 A drug demonstrating anxiolytic effect based on hydrogenated pyrido (4,3-b) indoles, its pharmacological compound and application method |
| 01/08/2009 | CA2691807A1 Stereoisomers of tricyclodecan-9-yl-xanthogenate |
| 01/08/2009 | CA2691746A1 Use of alpha-ketoglutarate in the treatment of hypertension |
| 01/08/2009 | CA2691736A1 Combination of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid and lopinavir for the treatment of a viral infection in a human |
| 01/08/2009 | CA2691716A1 Targeting diazo prodrugs for the treatment of gastrointestinal diseases |
| 01/08/2009 | CA2691704A1 4-imidazolines and their use as antidepressants |
| 01/08/2009 | CA2691677A1 Nanoassembled complexes of nucleic acids, avidin and polymers, use and preparation thereof |
| 01/08/2009 | CA2691662A1 Imidazole derivatives as ccr2 receptor antagonists |
| 01/08/2009 | CA2691646A1 Acne therapeutic agent and sebum secernent inhibitor which comprise indole-3-alkylcarbo xylicacid, and kits for photodynamic therapy containing the same |
| 01/08/2009 | CA2691638A1 Piperidine derivatives useful as orexin receptor antagonists |
| 01/08/2009 | CA2691625A1 Substituted 6-anilinopurine derivatives as inhibitors of cytokinin oxidase/dehydrogenase and preparations containing these derivatives |
| 01/08/2009 | CA2691615A1 Novel compounds 951: a biphenyloxypropanoic acid as crth2 modulator and intermediates |
| 01/08/2009 | CA2691587A1 Potentiation of cancer chemotherapy by 7-(2,5-dihydro-4-imidazo [1,2-a] pyrine-3-yl-2,5-dioxo-ih-pyrrol-3-yl)-9-fluoro-1,2,3,4, tetrahydro-2-(1-piperidinyl-carbonyd-pyrrolo[3,2,1-jk][1,4]benzodiazepin |
| 01/08/2009 | CA2691575A1 Use of piperine and derivatives thereof for the therapy of neurological conditions |
| 01/08/2009 | CA2691485A1 Chemical compounds |
| 01/08/2009 | CA2691459A1 Phthalazinone derivatives as inhibitors of parp-1 |
| 01/08/2009 | CA2691444A1 Purine derivatives and their use as modulators of toll-like receptor 7 |
| 01/08/2009 | CA2691442A1 Antiviral compounds |
| 01/08/2009 | CA2691373A1 3-aza-bicyclo[3.3.0]octane compounds |
| 01/08/2009 | CA2691201A1 2-substituted isoflavonoid compounds, medicaments and uses |
| 01/08/2009 | CA2691178A1 Novel triazene compounds for the treatment of cancer |
| 01/08/2009 | CA2691107A1 Pharmaceutical combination of nsaid and prostaglandin compound |
| 01/08/2009 | CA2691102A1 Pharmaceutical combination of opioid and prostaglandin compound |
| 01/08/2009 | CA2691082A1 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| 01/08/2009 | CA2690753A1 Sulfonamide compound and crystal thereof |
| 01/08/2009 | CA2690479A1 Method for preparing lipid nanoparticles |
| 01/08/2009 | CA2690440A1 Oligosialic acid derivatives, methods of manufacture, and immunological uses |
| 01/08/2009 | CA2690229A1 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| 01/08/2009 | CA2689466A1 Direct dissolution of docetaxel in a solvent in polysorbate 80 |
| 01/08/2009 | CA2689116A1 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof |
| 01/08/2009 | CA2681813A1 Transcription factor modulating compounds and methods of use thereof |
| 01/07/2009 | EP2011800A2 Inhibitors of caspase |
| 01/07/2009 | EP2011796A1 Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof |
| 01/07/2009 | EP2011788A1 Oxadiazolidinedione compound |
| 01/07/2009 | EP2011786A1 Indane-amine derivatives, their preparation and use as medicaments |
| 01/07/2009 | EP2011516A1 Method of producing polymer micelle having low molecular chemical encapsulated therein |
| 01/07/2009 | EP2011512A1 An anti HSP90 antibody |
| 01/07/2009 | EP2011507A2 Pharmaceutical composition of nateglinide and another antidiabetic agent |
| 01/07/2009 | EP2011503A2 High affinity nucleic acid ligands of cytokines |
| 01/07/2009 | EP2011502A1 Silicon containing compounds and their use as anti-inflammatory agents |
| 01/07/2009 | EP2011501A1 Compounds with chelation affinity and selectivity for first transition series elements and their use |
| 01/07/2009 | EP2011500A1 Fat accumulation inhibitor |
| 01/07/2009 | EP2011499A2 Pyrrolo[2,3d]Pyrimidine compositions and their use |
| 01/07/2009 | EP2011498A1 Brain function-improving agent, and functional food containing the improving agent |
| 01/07/2009 | EP2011497A1 Agent exhibiting a neurotropic, neuromodulator, cerebrovascular and anti- stroke activity |
| 01/07/2009 | EP2011496A1 Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
| 01/07/2009 | EP2011495A1 Use of piperine and derivatives thereof for the therapy of neurological conditions |
| 01/07/2009 | EP2011494A1 Agent for amelioration of dysphagia, and pharmaceutical or food composition comprising the same |
| 01/07/2009 | EP2011493A1 Inhibitor of increase in postprandial blood insulin level |
| 01/07/2009 | EP2011492A1 Gip secretion inhibitor |
| 01/07/2009 | EP2011491A1 Anticonvulsive pharmaceutical compositions |
| 01/07/2009 | EP2011490A1 Beta adrenergic receptor ligand derivatives for modulating apoptosis |
| 01/07/2009 | EP2011489A2 Method to inhibit ischemia and reperfusion injury |
| 01/07/2009 | EP2011488A1 Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process |
| 01/07/2009 | EP2011486A1 Pharmaceutical compositions of rifaximin |
| 01/07/2009 | EP2011485A2 Once-a-day oxycodone formulations |
| 01/07/2009 | EP2011484A2 Use of a dry powder composition of formoterol in the treatment of chronic obstructive pulmonary disease |
| 01/07/2009 | EP2011482A1 Solid preparation for oral application |
| 01/07/2009 | EP2010921A2 Method for diagnosing cardiovascular diseases |
| 01/07/2009 | EP2010916A2 Novel tumour suppressor |
| 01/07/2009 | EP2010658A2 Gene therapy for cancer using small interfering rna specific to ant2 and a method to overcome tolerance to antitumor agent |
| 01/07/2009 | EP2010570A2 Therapy against cathepsin s |
| 01/07/2009 | EP2010564A2 The homeobox transcription factor bsx and uses thereof for treating diseases, in particular obesity |
| 01/07/2009 | EP2010555A2 Method for preparing 4-[17beta -methoxy-17 -alpha methoxymethyl-3-oxoestra-4,9-dien-11beta -yl]benzaldehyde (e)-oxime (asoprisnil) |
| 01/07/2009 | EP2010553A1 Substituted adenines and the uses thereof |
| 01/07/2009 | EP2010551A1 Improved treatment of cystic fibrosis |
| 01/07/2009 | EP2010540A1 Spiro-imidazo compounds |
| 01/07/2009 | EP2010539A2 Stereoselective reduction of a morphinone |
| 01/07/2009 | EP2010537A1 Imidazoquinoxaline compounds as immunomodulators |
| 01/07/2009 | EP2010536A1 Imidazo [1, 2-b]pyridazines, their processes of preparation and their use as gaba receptor ligands |
| 01/07/2009 | EP2010535A1 Thioxanthine derivatives and their use as inhibitors of mpo |
| 01/07/2009 | EP2010534A1 Thioxanthine derivatives and their use as inhibitors of mpo |
| 01/07/2009 | EP2010533A2 Process for the preparation of 2,6,9-trisubstituted purines |
| 01/07/2009 | EP2010532A1 Tryclic nitrogen containing compounds and their use as antibacterials |
| 01/07/2009 | EP2010531A1 Spirocyclic cyclohexane derivative with analgesic properties |
| 01/07/2009 | EP2010529A1 Compositions and methods for modulating gated ion channels |
| 01/07/2009 | EP2010528A2 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| 01/07/2009 | EP2010526A1 Benzimidazole 5-sulfonamide derivatives as cannabinoid 1 (cb1) receptor ligands |
| 01/07/2009 | EP2010525A2 Diketo-piperazine and piperidine derivatives as antiviral agents |
| 01/07/2009 | EP2010524A2 S1p receptor modulating compounds |
| 01/07/2009 | EP2010521A1 Indazole compounds and methods for inhibition of cdc7 |
| 01/07/2009 | EP2010520A1 Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
| 01/07/2009 | EP2010519A2 Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators |
| 01/07/2009 | EP2010518A1 Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors |
| 01/07/2009 | EP2010517A1 Vaccine against nicotine addiction |